Study guide
5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management
Advanced Oncology Certified Nurse Practitioner AOCNP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide
2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening
2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling
3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging
3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment
4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship
4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence
5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy
5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring
6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies
6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology
7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy
7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies
8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response
8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)
9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety
9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions
10 Chapter 10: Supportive Care - Symptom & Comorbidity Management
10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management
11 Chapter 11: Oncologic Emergencies
11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH
12 Chapter 12: Psychosocial Issues
12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources
13 Chapter 13: Professional Practice & Roles of the APRN
13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education
5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management
Key Takeaways Explain This Topic AI
Alkylating agents and platinum compounds cause distinct organ-specific toxicities: cyclophosphamide and ifosfamide require Mesna and hyperhydration to prevent acrolein-induced hemorrhagic cystitis, while cisplatin causes nephrotoxicity requiring aggressive saline hydration.
Anthracyclines (doxorubicin, epirubicin) carry a cumulative lifetime dose-dependent cardiotoxicity limit (doxorubicin cap 450–550 mg/m²); Dexrazoxane is indicated as a cardioprotectant for high cumulative exposures and as an antidote for extravasation.
Taxanes and vinca alkaloids disrupt microtubule dynamics; taxanes cause neutropenia and peripheral neuropathy requiring steroid/antihistamine premedication, whereas vincristine causes dose-limiting neurotoxicity and is FATAL if administered intrathecally.
Antimetabolites (5-FU, capecitabine, methotrexate) target S-phase DNA synthesis; high-dose methotrexate (>500 mg/m²) requires urinary alkalinization and Leucovorin rescue, while Uridine Triacetate serves as the specific antidote for 5-FU/capecitabine overdose or early severe toxicity.
Irinotecan causes dual-phase diarrhea: acute cholinergic diarrhea occurring within 24 hours (treated with IV/SC atropine) and delayed secretory diarrhea occurring after 24 hours (treated with high-dose loperamide).
Last updated: August 2026
3.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management
Clinical Pearl: Intrathecal administration of vincristine is uniformly fatal, inducing progressive ascending radiculomyeloencephalopathy. To prevent accidental intrathecal administration, vincristine must never be prepared in a syringe; ONS guidelines mandate dispensing vincristine exclusively in a small-volume intravenous piggyback (flexbag) labeled with prominent warning stickers: "FOR INTRAVENOUS USE ONLY — FATAL IF GIVEN BY OTHER ROUTES."
Alkylating Agents & Platinum Compounds
Alkylating agents and platinum analogs form covalent DNA cross-links, inhibiting DNA replication and transcription. These agents are cell cycle-nonspecific (CCNS).
Nitrogen Mustards & Oxazaphosphorines
Cyclophosphamide & Ifosfamide: Undergo hepatic cytochrome P450 bioactivation to form mustard active species and toxic metabolite acrolein . Acrolein accumulates in the urinary bladder, inducing urothelial ulceration and severe hemorrhagic cystitis .
Prevention & Management: Concurrent administration of Mesna (2-mercaptoethanesulfonate), which binds acrolein in the bladder to form an inactive thioether. Aggressive IV hyperhydration (2–3 L/m²/day) and frequent voiding are mandatory. Ifosfamide always requires Mesna; high-dose cyclophosphamide (≥ 50 mg/kg or 1500 mg/m²) requires Mesna.
Ifosfamide Encephalopathy: Caused by metabolite chloroacetaldehyde; treated with IV Methylene Blue (50 mg Q4H).
Platinum Analogs
Cisplatin: Highly emetogenic (HEC) platinum compound. Primary dose-limiting toxicity is nephrotoxicity (acute tubular necrosis, hypomagnesemia, hypokalemia) and ototoxicity (irreversible high-frequency hearing loss).
Prevention: Pre- and post-infusion hydration with 1–2 liters of 0.9% Normal Saline supplemented with 20 mEq/L KCl and 8 mEq/L MgSO₄. Mannitol diuresis is indicated for high doses (≥ 75 mg/m²).
Carboplatin: Less nephrotoxic and emetogenic than cisplatin; dose-limiting toxicity is myelosuppression (specifically severe thrombocytopenia with a delayed nadir at 21 days).
Oxaliplatin: First-line agent in colorectal cancer. Dose-limiting toxicity is neuropathy :
Acute Neurotoxicity: Cold-induced transient pharyngolaryngeal dysesthesia occurring during or within hours of infusion (triggered by cold fluids, cold air, touching cold objects). Patient education regarding avoiding cold exposure is critical.
Chronic Cumulative Neuropathy: Dose-dependent peripheral sensory neuropathy occurring at cumulative doses >780–850 mg/m².
Antimetabolites & S-Phase Inhibitors
Antimetabolites structurally mimic endogenous nucleosides, inhibiting key metabolic enzymes during the S-phase of the cell cycle.
Fluoropyrimidines (5-FU & Capecitabine)
Mechanisms: Inhibits thymidylate synthase (TS) and incorporates into RNA/DNA.
Toxicities: Continuous infusion 5-FU causes stomatitis, mucositis, and diarrhea; bolus 5-FU causes myelosuppression. Oral prodrug capecitabine causes severe Hand-Foot Syndrome (palmar-plantar erythrodysesthesia). Both cause rare coronary vasospasm/angina.
Antidote: Uridine Triacetate (Vistogard) is the FDA-approved oral antidote for 5-FU or capecitabine overdose or severe early-onset toxicities (e.g., in unrecognized DPYD deficiency). Must be administered within 96 hours of 5-FU completion.
Folic Acid Analogs (Methotrexate)
Mechanism: Competitive inhibition of dihydrofolate reductase (DHFR), blocking tetrahydrofolate synthesis.
High-Dose Methotrexate (HD-MTX ≥ 500 mg/m²): Causes severe acute kidney injury via intratubular drug precipitation.
Supportive Protocol: Maintain vigorous IV hydration and urinary alkalinization (pH ≥ 7.0 using NaHCO₃) to enhance methotrexate solubility.
Rescue Therapy: Leucovorin (folinic acid) bypasses DHFR inhibition, rescuing normal host tissues. Leucovorin dosing is titrated based on serial serum methotrexate levels.
Glucarpidase (Voraxaze): Recombinant carboxypeptidase enzyme indicated for toxic serum methotrexate levels (>1 µmol/L) in patients with delayed clearance due to renal impairment.
- Antitumor Antibiotics & Topoisomerase Inhibitors
- Anthracyclines (Doxorubicin, Epirubicin, Idarubicin)
Mechanisms: Intercalates DNA, inhibits Topoisomerase II, and generates free radicals.
Cardiotoxicity: Causes cumulative dose-dependent irreversible cardiomyopathy and congestive heart failure.
Lifetime Dose Caps: Doxorubicin cumulative dose must not exceed 450 – 550 mg/m² (lower cap of 400 mg/m² if prior mediastinal radiation). Baseline LVEF evaluation via Echocardiogram or MUGA scan is mandatory.
Cardioprotectant: Dexrazoxane (Zinecard) is an iron-chelating agent indicated to reduce doxorubicin-induced cardiotoxicity in metastatic breast cancer patients who have received a cumulative doxorubicin dose of ≥ 300 mg/m² and require continued therapy. Doxorubicin Exposure
- │
- ├─► Cumulative Dose < 300 mg/m² ──► Standard Infusion & LVEF Monitoring
- │
- ├─► Cumulative Dose >= 300 mg/m² ─► Consider Dexrazoxane Cardioprotection
- │
- └─► Cumulative Dose 450-550 mg/m² ─► Absolute Lifetime Dose Ceiling (Discontinue)
- Pulmonary Toxic Antibiotics (Bleomycin)
Bleomycin: Glycopeptide antibiotic causing DNA strand breaks. Lacks significant bone marrow suppression, but carries severe dose-dependent pulmonary toxicity (interstitial pneumonitis progressing to pulmonary fibrosis).
Lifetime Limit: Maximum lifetime cumulative dose of 400 units .
Surveillance: Baseline and periodic Pulmonary Function Tests (PFTs) assessing DLCO (diffusing capacity of the lung for carbon monoxide). A >15–20% drop in DLCO mandates drug discontinuation. High FiO2 during anesthesia triggers acute respiratory failure.
Topoisomerase I Inhibitors (Irinotecan)
Irinotecan: Causes dose-limiting diarrhea with two distinct mechanisms:
Acute Cholinergic Diarrhea: Occurs during or within 24 hours of infusion, accompanied by diaphoresis, abdominal cramps, and salivation. Caused by acetylcholinesterase inhibition. Treated with IV or SC Atropine (0.25 to 1.0 mg).
Delayed Secretory Diarrhea: Occurs >24 hours post-infusion due to mucosal damage from active metabolite SN-38. Treated immediately with high-dose Loperamide (4 mg at onset, then 2 mg Q2H until diarrhea-free for 12 hours).
- Antimicrotubule Agents
- Taxanes (Paclitaxel, Docetaxel, Cabazitaxel)
Mechanism: Hyper-stabilize polymerized microtubules, preventing mitotic spindle disassembly and causing M-phase arrest.
Paclitaxel: Formulated in Cremophor EL (polyoxyethylated castor oil), inducing severe hypersensitivity reactions (HSR) . Mandates premedication with Dexamethasone, Diphenhydramine, and an H2 antagonist.
Docetaxel: Causes severe fluid retention and pleural effusions; requires premedication with oral Dexamethasone (8 mg BID for 3 days starting the day before infusion).
Vinca Alkaloids (Vincristine, Vinblastine, Vinorelbine)
Mechanism: Inhibit tubulin polymerization, preventing mitotic spindle formation.
Vincristine: Minimal myelosuppression, but dose-limiting neurotoxicity (peripheral neuropathy, foot drop, paralytic ileus/severe constipation). Single doses capped at 2.0 mg to limit toxicity.